Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 20;23(11):954-960.
doi: 10.3779/j.issn.1009-3419.2020.101.37. Epub 2020 Aug 21.

[Research Progress on Lung Cancer Screening]

[Article in Chinese]
Yazhe Guan  1 , Meng Ren  1 , Dongli Guo  1 , Yutong He  1
Affiliations
Review

[Research Progress on Lung Cancer Screening]

[Article in Chinese]
Yazhe Guan et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Lung cancer is the most common malignant tumor in the world. The five-year survival rate is 19.7%, which seriously threatens human health. Lung cancer screening is an effective measure to reduce lung cancer mortality. Existing studies have shown that screening with low-dose computed tomography (LDCT) can reduce lung cancer deaths by 20%. Currently, lung cancer screening is recommended internationally and nationally. Studying the development status of lung cancer screening helps us to identify the high-risk groups of lung cancer, explore reasonable screening programs, improve the cost-effectiveness of screening and reduce the economic burden. Therefore, this article summarizes the current status of lung cancer screening, the cost-effectiveness of lung cancer screening and the existing problems as follows. .

【中文题目：肺癌筛查研究进展】 【中文摘要：肺癌是世界上最常见的恶性肿瘤，其5年生存率仅为19.7%，严重威胁人类健康。肺癌筛查是降低肺癌死亡率的有效措施，已有的研究证明用低剂量螺旋计算机断层扫描（low-dose computed tomography, LDCT）进行筛查可降低20%的肺癌死亡，目前国际和国内均建议进行肺癌筛查。研究肺癌筛查的发展现状有助于我们明确肺癌的高危人群，探索合理的筛查方案，提高筛查的成本效益，减轻经济负担。因此本文就肺癌筛查现状、肺癌筛查的成本效益以及存在的问题综述如下。 】 【中文关键词：肺肿瘤；筛查；成本效益】.

Keywords: Cost-effectiveness; Lung neoplasms; Screening.

PubMed Disclaimer

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Cao MM, Chen WQ. Epidemiology of lung cancer in China. Thorac Cancer. 2019;10(1):3–7. doi: 10.1111/1759-7714.12916. - DOI - PMC - PubMed
    1. Martín-Sánchez JC, Lunet N, González-Marrón A, et al. Projections in breast and lung cancer mortality among women: a bayesian analysis of 52 countries worldwide. Cancer Res. 2018;78(15):4436–4442. doi: 10.1158/0008-5472.CAN-18-0187. - DOI - PubMed
    1. Xing PY, Zhu YX, Wang L, et al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. Cancer Med. 2019;8(8):4055–4069. doi: 10.1002/cam4.2256. - DOI - PMC - PubMed
    1. Li F, Du X, Zhang H, et al. Next-generation sequencing of Chinese stage Ⅳ lung cancer patients reveals an association between EGFR mutation status and survival outcome. Clin Genet. 2017;91(3):488–493. doi: 10.1111/cge.12809. - DOI - PubMed

LinkOut - more resources